SI
SI
discoversearch

Biotech / Medical : MGNX -- MacroGenics
MGNX 19.06+4.8%12:14 PM ESTNews

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (43)8/3/2017 3:40:08 AM
From: Miljenko Zuanic  Read Replies (1) of 76
 
Keytruda: <Mechanism-based translational models with a focus on intratumor exposure prediction suggested robust clinical activity would be observed at doses =2 mg/kg Q3W. Conclusions: Pembrolizumab was well tolerated and associated with durable antitumor activity in multiple solid tumors. The lowest dose with full potential for antitumor activity was 2 mg/kg Q3W.>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

Copyright © 1995-2017 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.